Mind Medicine To Conduct $25.0 Million Bought Deal Financing

Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this morning, to the tune of $25.0 million. The financing is being lead by Canaccord Genuity, with funds from the financing to be used for a number of clinical development initiatives that the company has planned for the near term.

$25.0 million in gross proceeds is expected to be raised via the sale of 23,810,000 units of the company at $1.05 per unit. Each unit is to consist of one subordinate voting share as well as one half warrant. Each warrant contains an exercise price of $1.40 per share, and is valid for three years from the date of issuance.

An over-allotment option also exists for the financing, which if fully exercised would result in additional gross proceeds of $3.75 million, bringing the total financing to $28.75 million. The over-allotment option is valid for a period of thirty days following the close of the transaction.

The proceeds from the financing are to be used for a number of clinical developments and initiatives, including:

  • Development of 18-MC
  • LSD microdosing
  • LSD experiential therapy for anxiety
  • MindMed Discover R&D
  • A training program at NYU Langone Health
  • A collaboration with University Hospital Basel Liechti Lab

Naturally, any remaining funds will be utilized for general working capital.

The financing is expected to close by October 30, 2020.

Mind Medicine last traded at $1.24 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

MindMed Presents Positive Data Studying LSD In Treating Anxiety Disorders

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today that its top...

Wednesday, May 11, 2022, 10:27:55 AM

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM

MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the...

Wednesday, September 21, 2022, 11:23:00 AM

MindMed Launches Clinical Trial Focused On Combining LSD With MDMA

Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and...

Wednesday, January 20, 2021, 08:09:53 AM

Mind Medicine Returns To Trough For Further $25.0 Million

Mind Medicine (NEO: MMED) continues to take investor dollars, this morning announcing a bought deal...

Wednesday, November 25, 2020, 09:25:41 AM